Akebia Therapeutics, Inc.
AKBA
$1.65
$0.106.45%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 24.23% | -14.25% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 24.23% | -14.25% | |||
| Cost of Revenue | 37.27% | -32.72% | |||
| Gross Profit | 21.78% | -9.59% | |||
| SG&A Expenses | 4.37% | -1.49% | |||
| Depreciation & Amortization | -0.01% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.34% | -4.66% | |||
| Operating Income | 19.24% | -43.32% | |||
| Income Before Tax | -13.80% | -133.50% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -13.80% | -133.50% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -13.80% | -133.50% | |||
| EBIT | 19.24% | -43.32% | |||
| EBITDA | 75.92% | -557.08% | |||
| EPS Basic | -9.44% | -133.01% | |||
| Normalized Basic EPS | 10.76% | -132.42% | |||
| EPS Diluted | -9.44% | -133.01% | |||
| Normalized Diluted EPS | 10.76% | -132.42% | |||
| Average Basic Shares Outstanding | 3.97% | 0.31% | |||
| Average Diluted Shares Outstanding | 3.97% | 0.31% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
